Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (417)

10/1/2018 6:06:45 PM

From: Miljenko Zuanic

Read Replies (1) | Respond to of 507

Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic Stage IV melanoma

Adi Diab1; Scott Tykodi; Brendan D. Curti2; Daniel C. Cho3; Michael K. Wong; Igor Puzanov4; Karl D. Lewis5; Michele Maio6; Gregory A. Daniels7; Alexander I. Spira8; Mary A. Tagliaferri9; Michael Imperiale; Alison L. Hannah; Wendy Clemens; Chantale Bernatchez; Jonathan Zalevsky10; Ute Hoch11; Christie Fanton12; Ahsan N. Rizwan13; Sandra Aung14; Fiore Cattaruzza; Ernesto Iaccucci; Dariusz Sawka; Mehmet A. Bilen15; Paul Lorigan; Giovanni Grignani; James Larkin16; Sekwon Jang17; Ewa Kalinka-Warzocha18; Mario Sznol19; Michael E. Hurwitz20; Adi Diab21; Salah Eddine Bentebibel; Cara Haymaker22

1University of Texas MD Anderson Cancer C; 2Earle A. Chiles Research Institute, Prov; 3NYU Medical Oncology Associates; 4Roswell Park Comprehensive Cancer Center; 5University of Colorado; 6University Hospital of Siena; 7University of California San Diego Moore; 8Virginia Cancer Specialists Research Institute; 9Nektar Therapeutics; 10Nektar Therapeutics; 11Nektar; 12Nektar Therapeutics; 13Nektar Therapeutics; 14Nektar Therapeutics; 15Winship Cancer Institute of Emory Univer; 16Royal Marsden Hospital; 17Inova Schar Cancer Institute; 18Polish Mothers Memorial Hospital; 19Yale Cancer Center; 20Yale Cancer Center; 21University of Texas MD Anderson Cancer C; 22University of Texas MD Anderson Cancer Center

To: Miljenko Zuanic who wrote (417)	10/4/2018 2:12:52 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 507

<The e-mail continues: Modified T Reg Increase in the Peripheral Blood and Not in the Tumor NKTR-214 was designed to avoid Treg accumulation in the tumor microenvironment. Our earliest preclinical studies demonstrated the ability to promote transient Treg elevations in the peripheral blood, but not the tumor. Inherent to its design, it is necessary to preserve some binding to IL-2R-alpha because that receptor is needed for T-cell priming reactions in the lymph node. This does not make any sense to us. There is no viable explanation for why NKTR-214 would have the same impact on peripheral Tregs as IL-2 but magically prevent those Tregs from entering in the tumor microenvironment—unless Tregs simply don’t accumulate in the tumor microenvironment, in which case IL-2 also does not cause a Treg increase in the tumor microenvironment and NKTR-214 is not actually adding any value.> From SA, refute on NKTR short refute report: seekingalpha.com Main issue on this ongoing debate is 1) Treg/Tefect (Cd4+ v CD8+) anti-tumor immune response, 2) peripheral lymphocyte proliferation and level increase versus intratumoral (localized) ----> therapeutic effect versus toxic effect,....3) additive/cumulative versus diminished drug-combination approaches??? Both side have points to make.....but, clinical data are one that will prove one or other. So far NKTR is loosing,....any further delay in PIVOT data presentation will add more fuel on fire! My Q is: "Are oncologist/researchers at Anderson Cancer Center that stupid to promote something in Abstract Title that dose not make ANY SENSE in real world????"